Study of Ibrutinib in Combination With Revlimid/Dexamethasone in Relapsed/Refractory Multiple Myeloma

  • STATUS
    Recruiting
  • days left to enroll
    15
  • participants needed
    28
  • sponsor
    Alliance Foundation Trials, LLC.
Updated on 22 June 2021
platelet count
stem cell transplantation
filgrastim
monoclonal antibodies
granulocyte colony stimulating factor
measurable disease
growth factor
bone marrow procedure
dexamethasone
lenalidomide
colony stimulating factor
progressive disease
neutrophil count
monoclonal antibody therapy
g-csf
monoclonal protein
revlimid
immunoglobulin
immunoglobulins
electrophoresis
daratumumab
ibrutinib
therapeutic regimen
refractory multiple myeloma
serum immunoglobulin a
kappa light chain

Summary

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

Description

The study will be completed in two parts: Dose escalation and dose expansion.

Dose Escalation Starting doses of ibrutinib and lenalidomide will be assigned at the time of registration. A minimum of 2 or a maximum of 6 patients will be accrued to a given dose level. Doses will not be escalated in any individual patient.

If none of the first 3 patients treated at a given dose level develops a dose limiting toxicity during the first cycle of treatment, enrollment to the dose level will be closed and enrollment will reopen at next higher dose level. If there are no other higher dose levels to be tested, three additional patients will be enrolled at the current dose level to confirm maximum tolerated dose. If one of the first 3 patients treated at a given dose level develops a dose limiting toxicity during the first cycle of treatment, three additional patients will be enrolled onto the current dose level. If, at any time in the enrollment of these 3 additional patients, a patient develops a dose limiting toxicity, enrollment will be closed to this dose level. Enrollment will be re-opened to the next lower dose level if fewer than 6 patients have been treated at that dose level. If none of these 3 additional patients develops a dose limiting toxicity during the first cycle of treatment, enrollment to this dose level will be closed and enrollment will reopen at next higher dose level. If there are no other higher dose levels to be tested, this will be considered the maximum tolerated dose.

Patients will return to the clinic every 28 days for physical exams, laboratory assessments and review of side effects.

Patients who do not have disease progression and have not experienced unacceptable toxicities will be eligible to continue protocol treatment at their current dose level until disease progression, unacceptable toxicity, or refusal. Those patients who have not experienced progression of disease but have unacceptable toxicity may be eligible for re-treatment at a lower dose.

Part 2: Dose Expansion Once the maximum tolerated dose has been established or determined, 10 additional patients will be treated at the maximum tolerated dose of lenalidomide and ibrutinib at the same schedule as above. Dexamethasone will be given at the same dose as in the dose escalation portion of the study.

Patients who discontinue treatment for protocol defined reasons will go to survival follow-up. Once a patient has entered the survival follow-up phase of the trial, his/her therapy is at the discretion of the treating physician. Patients' charts will be reviewed for progression and survival endpoints during visits with treating physicians.

Details
Condition Lymphoproliferative Disorder, Multiple Myeloma, Multiple Myeloma in Relapse, Lymphoproliferative disorders, multiple myeloma (mm), Refractory Multiple Myeloma
Treatment Ibrutinib, Dexamethasone, Lenalidomide
Clinical Study IdentifierNCT03702725
SponsorAlliance Foundation Trials, LLC.
Last Modified on22 June 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Men and women 18 years
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1 (Appendix I)
Symptomatic multiple myeloma (MM) (as defined by revised IMWG criteria) with measurable disease, defined here as having at least one of the following
Serum monoclonal protein 0.5 g/dL
mg of monoclonal protein in the urine on 24 hour electrophoresis
Serum immunoglobulin free light chain (FLC): involved FLC 10 mg/dL ( 100 mg/L) AND abnormal serum immunoglobulin kappa to lambda free light chain ratio
At least 2 prior therapies with demonstrated disease progression following the most recent line of treatment
Progression of disease within 60 days of completion of last therapeutic regimen or the failure to achieve minimal response while on last treatment (according to IMWG)
Patients can have received prior lenalidomide but cannot be refractory to the agent. Disease considered refractory to prior lenalidomide- containing regimens is defined
as
Disease that is nonresponsive while on therapy or progresses within 60 days of last therapy. Nonresponsive disease is defined as either failure to achieve minimal response or development of progressive disease while on treatment
Patients who experience disease progression on lenalidomide maintenance at a dose < 10 mg are eligible to participate
No prior treatment with ibrutinib or any other protein kinase inhibitory drug or drug targeting the b-cell receptor (BCR) signal transduction pathway
Patients with prior daratumumab and allogeneic stem cell transplant are included
PT/INR <1.5 x ULN and PTT (aPTT) <1.5 x ULN, except if on anticoagulation for medical reasons in which case INR should be 3
Adequate hematologic function independent of transfusion and growth factor support for at least 7 days prior to registration, with the exception of pegylated G-CSF (pegfilgrastim) and darbopoeitin which require at least 14 days prior to screen and enrollment defined as
Absolute neutrophil count (ANC) 1000/mm3 independent of growth factor support
Transfusion independent platelet counts 75,000/mm3 (or 50,000/mm3 if bone marrow involvement is 50%)
Hemoglobin level 8 g/dL, independent of transfusion support
Biochemical values must be within the following limits within 7 days prior to registration
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 x upper limit of normal (ULN)
Total bilirubin 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
Serum creatinine 2 x ULN or GFR > 30 ml/min based on either the estimated Glomerular Filtration Rate (Crockcoft Gault) or measured GFR from 24-hour urine sample. Study participants with GFR 30-50 ml/min will be treated according to manufacturer's instruction with lenalidomide 10mg rather than 25 mg
Ability to understand and willingness to sign a written informed consent form (ICF)
Ability to adhere with the study visit schedule and other protocol procedures
A negative pregnancy test will be required for all women of child bearing potential within 7 days prior to registration. Breast feeding is not permitted
Fertility requirements
Female patients with child bearing potential must have a negative pregnancy test at least 7 days before starting treatment drugs
Male subject must use an effective barrier method of contraception during the study and for 3 months following the last dose if sexually active with a female of childbearing potential
Female patients must be either post-menopausal, free from menses 2yrs, surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from sexual activity starting from screening and for 90 days after lenalidomide treatment
Female patients of childbearing potential must agree to comply with the fertility and pregnancy test requirements dictated by the Rev-Assist program
Willingness to provide blood and tissue samples for correlative research purposes

Exclusion Criteria

Prior history of: Polyneuropathy, organomegaly, endocrinopathy, M-protein, and skin changes (POEMS) syndrome, osteosclerotic myeloma, Crow-Fukase syndrome, primary amyloidosis or plasma cell leukemia
Radiotherapy within 21 days of registration. However, if the radiation portal was localized to single lesion or fracture site and covered by 5% of the bone marrow reserve (by investigator estimate), the subject may be enrolled irrespective of the end date of radiotherapy
Prior chemotherapy
Alkylators (e.g. melphalan, cyclophosphamide) 21 days prior to registration and/or monoclonal antibody 6 weeks prior to first administration of study treatment
Anthracyclines 21 days prior to registration
High dose corticosteroids, immune modulatory drugs (thalidomide or lenalidomide), or proteasome inhibitors (bortezomib or carfilzomib) 14 days prior to registration
No concomitant high dose corticosteroids (concurrent use of corticosteroids). EXCEPTION: Patients may be on chronic steroids (maximum dose 10 mg/day prednisone equivalent) if they are being given for disorders other than myeloma, i.e., adrenal insufficiency, rheumatoid arthritis, etc
Currently active, clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias or Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to registration or baseline QTcF of > 470\
Unable to swallow capsules or disease significantly affecting gastrointestinal function, such as malabsorption syndrome, resection of the stomach or small bowel, or complete bowel obstruction
History of prior malignancy, with the exception of the following
Malignancy treated with curative intent and with no known active disease present for more than 3 years prior to registration and felt to be at low risk for recurrence by treating physician
Adequately treated non melanoma skin cancer or lentigo maligna without current evidence of disease; or
Adequately treated breast or cervical carcinoma in situ without current evidence of disease
Peripheral neuropathy Grade > 2 on clinical examination within 14 days prior to registration
Uncontrolled diabetes mellitus
Currently active systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment)
Use of antibiotics for treatment of infection within 14 days prior to registration
Recent infection requiring systemic treatment that was completed within 14 days of registration
Known infection with human immunodeficiency virus (HIV) or active infection with hepatitis C virus (HCV) or hepatitis B virus (HBV) or any uncontrolled active systemic infection
Note: Subjects who are positive for hepatitis B core antibody, hepatitis B
surface antigen, or hepatitis C antibody must have a negative polymerase chain
reaction (PCR) result within 14 days prior to registration
\. History of stroke or intracranial hemorrhage within 6 months prior to
registration
\. Patients who received a strong cytochrome P450 (CYP) 3A inhibitor within
days prior to the first dose of ibrutinib or patient who requires continuous
treatment with a strong CYP3A inhibitor (Appendix II)
\. Currently active, clinically significant hepatic impairment (Child-Pugh
class B or C) according to the Child Pugh classification (Appendix III)
\. Lactating or pregnant
\. Major surgery within 4 weeks prior to registration
\. Known bleeding disorders (e.g. von Willebrand's disease or hemophilia)
\. Allergies and adverse drug reactions: history of allergy to study drug
components
\. Vaccinated with live, attenuated vaccines within 4 weeks of first dose of
study drug
\. Any life-threatening illness, medical condition, or organ systemic
dysfunction that, in the investigator's opinion, could compromise the
subject's safety or put the study outcomes at undue risk
\. Unresolved toxicities from prior anti-cancer therapy, defined as not
having resolved to CTCAE Version 5.0, Grade 0 or 1, with the exception of
alopecia
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note